Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma

Title: Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma

Abstract

A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.

Inventors:: Jurisson, Silvia S.; Quinn, Thomas P.; Giblin, Michael F.

Issue Date:: 2003-08-19

Research Org.:: Univ. of Missouri, Columbia, MO (United States)

Sponsoring Org.:: USDOE

OSTI Identifier:: 1531460

Patent Number(s):: 6,607,709

Application Number:: 09/686,700

Assignee:: The Curators of the University of Missouri (Columbia, MO)

DOE Contract Number:: FG02-93ER61661

Resource Type:: Patent

Resource Relation:: Patent File Date: 2000-10-11

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE

Citation Formats


                    Jurisson, Silvia S., Quinn, Thomas P., and Giblin, Michael F. Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma.  United States: N. p., 2003. 
        Web.

Copy to clipboard


                    Jurisson, Silvia S., Quinn, Thomas P., & Giblin, Michael F. Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma.  United States.

Copy to clipboard


                    Jurisson, Silvia S., Quinn, Thomas P., and Giblin, Michael F. Tue .  
        "Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma".  United States.  https://www.osti.gov/servlets/purl/1531460.

Copy to clipboard


                    
@article{osti_1531460,

  title        = {Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma},

  author       = {Jurisson, Silvia S. and Quinn, Thomas P. and Giblin, Michael F.},

  abstractNote = {A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {2003},

  month        = {8}

}

Copy to clipboard

Patent:

View Patent

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Synthetic analogues of .alpha.-melanotropin
patent, November 1984

Hruby, Victor J.; Hadley, Mac E.; Sawyer, Tomi K.
US Patent Document 4,485,039
URL: http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=4485039

Works referencing / citing this record:

Metal abstraction peptide (MAP) tag and associated methods
patent, March 2015

Stowell Laurence, Jennifer Ann; Vartia, Anthony Andrew; Krause, Mary Elizabeth
US Patent Document 8,975,082
URL: http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=8975082

Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting
patent, October 2016

Miao, Yubin
US Patent Document 9,463,255
URL: http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=9463255

Metal abstraction peptide (MAP) tag and associated methods
patent, August 2015

Stowell Laurence, Jennifer Ann; Vartia, Anthony Andrew; Krause, Mary Elizabeth
US Patent Document 9,096,652
URL: http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=9096652

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
patent, August 2018

Miao, Yubin
US Patent Document 10,047,135
URL: http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=10047135

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
patent, March 2015

Miao, Yubin; Guo, Haixun
US Patent Document 8,986,651
URL: http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=8986651

Metal abstraction peptide with superoxide dismutase activity
patent, November 2015

Stowell Laurence, Jennifer Ann; Krause, Mary Elizabeth; Jackson, Timothy A.
US Patent Document 9,187,735
URL: http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=9187735

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
patent, November 2016

Miao, Yubin; Guo, Haixun
US Patent Document 9,493,537
URL: http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=9493537

Similar records in DOE Patents and OSTI.GOV collections:

Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma

Patent Jurisson, Silvia S.; Quinn, Thomas P.; Giblin, Michael F.

A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.
Full Text Available
Methylthioadenosine phosphorylase compositions and methods of use in the diagnosis and treatment of proliferative disorders

Patent Olopade, Olufunmilayo I.

Disclosed are novel nucleic acid and peptide compositions comprising methythlioadenosine phosphorylase (MTAP) and methods of use for MTAP amino acid sequences and DNA segments comprising MTAP in the diagnosis of human cancers and development of MTAP-specific antibodies. Also disclosed are methods for the diagnosis and treatment of tumors and other proliferative cell disorders, and idenification tumor suppressor genes and gene products from the human 9p21-p22 chromosome region. Such methods are useful in the diagnosis of multiple tumor types such as bladder cancer, lung cancer, breast cancer, pancreatic cancer, brain tumors, lymphomas, gliomas, melanomas, and leukemias.
Full Text Available
Compositions and methods involving methyladenosine phosphorylase in the diagnosis and treatment of proliferative disorders

Patent Olopade, Olufunmilayo I.

Disclosed are novel nucleic acid and peptide compositions comprising methylthioadenosine phosphorylase (MTAP) and methods of use for MTAP amino acid sequences and DNA segments comprising MTAP in the diagnosis of human cancers and development of MTAP-specific antibodies. Also disclosed are methods for the diagnosis and treatment of tumors and other proliferative cell disorders, and identification of tumor suppressor genes and gene products from the human 9p21-p22 chromosome region. Such methods are useful in the diagnosis of multiple tumor types such as bladder cancer, lung cancer, breast cancer, pancreatic cancer, brain tumors, lymphomas, gliomas, melanomas, and leukemias.
Full Text Available
99M-Technetium labeled tin colloid radiopharmaceuticals

Patent Winchell, Harry S [Lafayette, CA]; Barak, Morton [Walnut Creek, CA]; Van Fleet, III, Parmer (Walnut Creek, CA)

An improved 99m-technetium labeled tin(II) colloid, size-stabilized for reticuloendothelial organ imaging without the use of macromolecular stabilizers and a packaged tin base reagent and an improved method for making it are disclosed.
Full Text Available
Process for preparing radiopharmaceuticals

Patent Barak, Morton [Walnut Creek, CA]; Winchell, Harry S [Lafayette, CA]

A process for the preparation of technetium-99m labeled pharmaceuticals is disclosed. The process comprises initially isolating technetium-99m pertechnetate by adsorption upon an adsorbent packing in a chromatographic column. The technetium-99m is then eluted from the packing with a biological compound to form a radiopharmaceutical.
Full Text Available

Similar Records

Title: Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma

Abstract

Citation Formats

Synthetic analogues of .alpha.-melanotropin patent, November 1984

Metal abstraction peptide (MAP) tag and associated methods patent, March 2015

Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting patent, October 2016

Metal abstraction peptide (MAP) tag and associated methods patent, August 2015

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same patent, August 2018

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same patent, March 2015

Metal abstraction peptide with superoxide dismutase activity patent, November 2015

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same patent, November 2016

Synthetic analogues of .alpha.-melanotropin
patent, November 1984

Metal abstraction peptide (MAP) tag and associated methods
patent, March 2015

Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting
patent, October 2016

Metal abstraction peptide (MAP) tag and associated methods
patent, August 2015

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
patent, August 2018

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
patent, March 2015

Metal abstraction peptide with superoxide dismutase activity
patent, November 2015

Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
patent, November 2016